indanocine: a microtubule-binding indanone with antiproliferative activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5353680 |
| CHEMBL ID | 562718 |
| MeSH ID | M0357712 |
| Synonym |
|---|
| indanocine |
| CHEMBL562718 |
| (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one |
Indanocine is a synthetic indanone that has been identified by the National Cancer Institute's Developmental Therapeutics Program as having antiproliferative activity. It is a potent tubulin-binding drug that is cytotoxic to multidrug-resistant cancer cell lines.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Indanocine is a synthetic indanone that has been identified by the National Cancer Institute's Developmental Therapeutics Program as having antiproliferative activity." | ( Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. Carrera, CJ; Carson, DA; Cottam, HB; Genini, D; Hamel, E; Leoni, LM; Shih, H, 2000) | 2.47 |
| "Indanocine is a cytostatic and cytotoxic indanone that blocks tubulin polymerization but, unlike other antimitotic agents, induces apoptotic cell death in stationary-phase multidrug-resistant cancer cells at concentrations that do not impair the viability of normal nonproliferating cells. " | ( Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. Carrera, CJ; Carson, DA; Cottam, HB; Genini, D; Hamel, E; Leoni, LM; Shih, H, 2000) | 3.19 |
| "Indanocine is a potent tubulin-binding drug that is cytotoxic to multidrug-resistant cancer cell lines. " | ( Biochemical genetic analysis of indanocine resistance in human leukemia. Carson, DA; Genini, D; Gussio, R; Hua, XH; Kipps, TJ; Leoni, LM; Shih, H; Tawatao, R, 2001) | 2.04 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Indanocine-treated cells were defective in lamellipodium formation and could not develop polarized morphology." | ( Kinetic stabilization of microtubule dynamics by indanocine perturbs EB1 localization, induces defects in cell polarity and inhibits migration of MDA-MB-231 cells. Kapoor, S; Panda, D, 2012) | 1.35 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID420737 | Inhibition of tubulin polymerization | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||